VRTX · News · 20261113N
Regulatory Approval Milestones
VERTEX PHARMACEUTICALS INC / MA · 2026-11-13 · Importance 34 · Surprise 42
Vertex is awaiting an FDA decision on povetacicept for IgA nephropathy, scheduled for November 30, 2026. The article says approval could expand the company’s commercial portfolio beyond cystic fibrosis but provides no quantified financial impact. Interim AMPLITUDE trial results for inaxaplin are expected in early 2027. The article also notes that investors are monitoring the JOURNAVX patient support program, without describing its financial implications.
Key facts
- The FDA decision on povetacicept for IgA nephropathy is scheduled for November 30, 2026. source